Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported its preliminary unaudited results for the fourth quarter and year ended 2022.
Preliminary (unaudited) 4th Quarter, Full Year 2022 Results:
Revenue for the fourth quarter of 2022 is expected to be approximately $6.0-$6.2 million, an increase of 46-51% compared to the same prior year period, primarily driven by an increase in PulseVet® sales and the inclusion of the recently acquired Assisi® products.
Revenue for the year ended 2022 is expected to be approximately $18.6-$18.9 million, an increase of 354-361% compared to the same prior year period, primarily driven by a full year's worth of PulseVet sales and the inclusion of the recently acquired Assisi products.
Gross Margin is expected to be approximately 72% for the full year 2022.
Cash, Cash Equivalents, and Available-for-Sale Securities are expected to be approximately $156 million as of December 31, 2022.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.